Drug Search Results
More Filters [+]

Asapiprant

Alternative Names: asapiprant, bge-175, bge 175, bge175, S-555739, S555739, S 555739
Latest Update: 2024-05-07
Latest Update Note: PubMed Publication

Product Description

asapiprant is a potent and selective DP1 receptor antagonist, and exerts suppressive effects in the animal models of allergic diseases. Thus, asapiprant has potential as a novel therapy for allergic airway diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26277322/)

Mechanisms of Action: PGD2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Asapiprant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Rhinitis, Allergic, Seasonal|Rhinitis, Allergic, Perennial

Phase 2: Rhinitis, Allergic, Perennial|Rhinitis, Allergic|Rhinitis, Allergic, Seasonal|COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BGE-175-201

P2

Terminated

COVID-19

2022-04-20

1210D1526

P2

Completed

Rhinitis, Allergic, Seasonal

2012-11-01

33%

2008-006788-35

P2

Completed

Rhinitis, Allergic

2009-07-17

2008-006787-11

P2

Completed

Rhinitis, Allergic

2009-05-30

Recent News Events